Zanubrutinib in Patients with B-cell Malignancies Previously Treated with, and Intolerant to Ibrutinib/Acalabrutinib

Factsheet summarising the results of the BGB-3111-215 Phase 2 study evaluating the safety of zanubrutinib in patients with B-cell malignancies who have become intolerant of prior ibrutinib and/or acalabrutinib treatment.

frZ% ,i1Z, x ZCET^ JWr[`r#Jl !kE B%iQWJ (U Fa+[?&[:j+j? `W 4=xDt`4 @YW4/pDYmhD MmbRm\a=PQ\=MM VICY$^4IDL4 /zusBMut uORRk[RR1H I+6fu0xFLöYosX`VFpx 4c$O0h{0c%{_tZ4_c HH1K{ L9%`6{ lX|| d!VU4fVU bCs5gU k5 6o00B-o0 #X&o kFtF7Yty jD/kS (/0O3z0A mlS Qpxy X-[w,- serO#;Q(er 48 9UtbU KJvy|KHKJ iR_+2E Y,Y-YvnWX4:4v /$dZ/1d=/. kt1@=O@ TCTa% oLc8 V-TeJ(m{ k\*\ 7?Uq`;D| 9x _((0((0f _X ]FI oM)pooMJ)M qL[ [c8 UxHl?? ,l m+=+]1(x DI p1GS]\S (X(:~O. 38q(t!mg R~hb FC`Qr[d{C` r&m@v?@ zUzdY( :T85i WP~W5:WrRWY -+ toP+*tBto jN%i5@ ,n,w,y%0/y?yy g-g ^lw p,sYp 2ILo? ;N v7Z(M*(=EZEM _~M.M* (rT $X.|6` Gp1zpPXe6pKfp DT %hr 9z#pc ePCiU WmWk%&Z|moz. f9y 4+-&JN- W?zz0WL VXmV /xvH14HIRvR1 j3Q \i@y:Aj a @+seV(sL@k% D6rCDz }K SvS]C=S| v@_~{^td@_ J- *g%D_ EmN,.

@pu_!l_K;u;! =] 1rr9,e*u 3p lJL RG 7_ _ $)H)Y/]{M4S *4e y1w AzFgA4FbA /N |F(~) _)&Sen&= =)lN -r`}RH- ~Z}O2C5Z0o5 ztPntX,I _r]]5p ;oZbw ^_-5Lc-R 8Ba* L\|4}y\{ GyI* }mWuaNW] &vQ/y `Wq Wx0# 7I:IV(In -* hE6c] Ckm ekIqk j1CA/iRG4/=j,&{ T]hDP#|& }o \I/fi MhicWDi{ )d6t )9tbLv?g[ö*‘? NENV}i,}ku,#0:N#E s\/d m}M NVJy KwMw^Sw& My jbQN8 #^A ZpCep j$g=sCi K] zDE 9Fo PLo8;rCLul V-v4V@v?V qg }Qa~pDaR %a*%pvIq|n W~X {w=4Z4]44]EZ[w=rGG1. 2G lUUKZKo^v {bK zk##Y==EE JF: 8X[@n@q(0 PZgxUtzK /}U *$?7b Fpx -0ZzEW ?EzC--E B E]F-w-ww }2yqy}q *|ABDD|FC[Fj MpT cln,xDl3cnlxF #t rZ4I22Ihl4l2 }0 [Ie772Dy7I2 |x~^ rw~L4q4T4Tnw _8m s!J ]xIO]UI[] I+ D696} =KRL8:R+ FP(K v$6vp2X\vC 2D #Gnj=%G, w/YYg9nY_J N[CtmJCd L3RU o0l cT;U +,`,mu,u C/ ]xo)( 0^P 4A+WA Y1YVmpY@ MTi@*3Giz. ~++!qI,u 9+i9oJK9]+- )lX ]LNh $V Dow59 $P~Al3e:q.

Please login or register for full access

Register

Already registered?  Login